, , , e.a.

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

Specificaties
Gebonden, blz. | Engels
Elsevier Science | e druk, 2013
ISBN13: 9780123948106
Rubricering
Elsevier Science e druk, 2013 9780123948106
€ 173,80
Levertijd ongeveer 8 werkdagen

Samenvatting

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics is a complete reference devoted to the nonclinical safety assessment of novel biopharmaceuticals, biosimilars, vaccines, cell and gene therapies and blood products. This book compares and contrasts these types of biologics with one another and with small molecule drugs, while incorporating the most current and essential international regulatory documents. Each section discusses a different type of biologic, as well as early characterization strategies, principles of study design, preclinical pharmacokinetics and pharmacodynamics and preclinical assays. An edited book that is authored by leading experts in the field, this comprehensive reference provides critical insights to all researchers involved in early through late stage biologics.

Specificaties

ISBN13:9780123948106
Taal:Engels
Bindwijze:Gebonden

Inhoudsopgave

<p>Preface<br>Acknowledgement<br>Dedication</p> <p>Section I: Biopharmaceuticals</p> <p>1. Novel Biopharmaceuticals <br>2. Global Regulatory Guidances<br>3. Early de-risking strategies for Novel Biopharmaceuticals vs. Small Molecule Drugs  <br>4. PK/PD assessments and Assays<br>5. Antibody-Drug Conjugates</p> <p><br>Section II: Biosimilar Therapeutics</p> <p>6. Description of Biosimilar Therapeutics and  Compare/contrast Biosimilar Therapeuticss and Novel Biopharmaceuticals <br>7. Global Regulatory Guidelines<br>8. Early characterization of Biosimilar Therapeutics vs. Novel Biopharmaceuticals/Studies Required and Principles of Study Design/PK/PD assessments/Assays</p> <p>Section III: Vaccines</p> <p>9. Vaccines Description and Comparison/Contrast of Vaccines and Novel Biopharmaceuticals<br>10. Global Regulatory Guidances<br>11. Early de-risking strategies for Vaccines vs. Novel Biopharmaceuticals  </p> <p>Section IV: Specialty Biologics and Indications</p> <p>12. Cell Therapies<br>13. Gene Therapies<br>14. Blood Products<br>15. Oncology Drugs<br>16. Dual and Multi-Function Modalities<br>17. Stem Cell-Based Therapeutics</p>
€ 173,80
Levertijd ongeveer 8 werkdagen

Rubrieken

    Personen

      Trefwoorden

        Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics